Search Results - therapeutics+%3e+oncology

131 Results

Sort By:

Generation of Therapeutic Human Anti-Trop-2 Extracellular Domain Antibodies (UCLA Case No. 2026-026)

UCLA researchers from the Department of Molecular and Medical Pharmacology and the Department of Microbiology, Immunology and Molecular Genetics have developed a panel of human antibodies and chimeric antigen receptors targeting Trop-2, providing diagnostic and therapeutic resources for targeting Trop2-driven cancer. BACKGROUND: Trophoblast cell surface...

Published: 12/23/2025 | Inventor(s): Tanya Stoyanova, Owen Witte

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Diagnostic Markers > Targets And Assays, Life Science Research Tools > Antibodies, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combinatorial RNA-LNP Immunotherapy for Enhanced Pattern Recognition Receptor (PRR) Engagement, Targeted Dendritic Cell (DC) Activation, and Versatile (UCLA Case No. 2025-237)

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a cancer immunotherapy platform that uses lipid nanoparticle (LNP) delivery of modified RNA constructs to activate dendritic cells, enhance CD8+ T-cell priming, and drive potent anti-tumor immunity. BACKGROUND: Effective cancer immunotherapy requires robust activation...

Published: 12/23/2025 | Inventor(s): Caius Radu

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Vaccines, Therapeutics > Infectious Diseases

B Cell-Based Assay to Expand Antigen-Specific T Cells (UCLA Case No. 2025-288)

UCLA researchers from the Department of Medicine have developed a novel B cell-based assay to expand antigen-specific T cells, allowing for an efficient, patient-specific platform to generate tumor antigen-specific T cells. BACKGROUND: Adoptive T cell therapies have emerged as a promising strategy for cancer immunotherapy, enabling the expansion of...

Published: 11/6/2025 | Inventor(s): Yuanyuan Tong, Willy Hugo, Maureen Su, Melissa Lechner, Robert Prins

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Silyl Ether Enables Chemoproteomic Interaction and Target Engagement (SEE-CITE) (UCLA Case No. 2024-194)

UCLA researchers from the Department of Biological Chemistry have developed a chemoproteomic platform for high-coverage, site-specific mapping of small-molecule–protein interactions using a cleavable silyl ether–based photoaffinity probe design. BACKGROUND: Small molecule drugs rely on specific and selective interactions with protein targets...

Published: 11/4/2025 | Inventor(s): Keriann Backus

Keywords(s):

Category(s): Life Science Research Tools > Mass Spectrometry, Life Science Research Tools > Research Methods, Therapeutics > Oncology

Pancreas Cancer Immunotherapy using Cationic Lipid and Polymer Nanocarriers for co-delivery of KRAS Neoantigens and STING or other immunomodulators to boost the Cancer Immunity Cycle and Treat Liver Metastasis (UCLA Case No. 2024-076)

UCLA researchers have developed a translational immunotherapy platform that leverages nanoparticle-based delivery of tumor-associated signals and immune-stimulatory molecules to drive localized immune activation in metastatic pancreatic cancer. This approach is designed to initiate de novo immune priming and recondition the tumor microenvironment in...

Published: 10/29/2025 | Inventor(s): Andre Nel

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Vaccines, Platforms > Drug Delivery

Cannabis Limits Cancer Stem Cell Growth in Poorly Differentiated Cancers (UCLA Case No. 2020-869)

Contact UCLA Technology Development Group for more information.

Published: 10/23/2025 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics > Oncology

Sonicated Osteoclasts as Drugs to Increase NK Expansion and Function in Patients and in Manufacturing of NK Cells (Case No. 2024-272)

UCLA researchers from the Department of Dentistry have developed an innovative method to manufacture, expand and improve the function of natural killer cells by using sonicated osteoclasts for cancer immunotherapy. BACKGROUND: Natural killer cells (NK cells) are immune cells that recognize and combat pathogens and cancer cells. NK cell immunotherapy...

Published: 10/23/2025 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

Curative Locoregional Therapy Using Ablation or Catheter-Based Embolization of Targeted Hepatocellular Carcinoma by Delivering Supercharged NK Cells and CAR-NK or CAR-T Cells (UCLA Case No. 2023-115)

UCLA researchers in the School of Dentistry and Interventional Radiology have developed a groundbreaking curative treatment for hepatocellular carcinoma that combines locoregional therapy, such as ablation or catheter-based embolization, with targeted delivery of supercharged NK cells and CAR-NK or CAR-T cells, offering a highly effective approach that...

Published: 10/31/2025 | Inventor(s): Anahid Jewett, Steven Raman, Jason Chiang

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

Combination Metabolic-Epigenetic Treatment for Early Lung Cancer (UCLA Case No. 2022-247)

UCLA researchers in the Division of Pulmonary Medicine at the School of Medicine uncovered a novel mechanism by which cancer cells adapt to glucose restriction and develop treatment resistance, and have in response developed a novel combination therapy to delay lung adenocarcinoma development while circumventing the development of aggressive behavior...

Published: 10/23/2025 | Inventor(s): Claudio Scafoglio

Keywords(s):

Category(s): Therapeutics > Oncology, Diagnostic Markers > Cancer

Combination of Insulin-like Growth Factor-1 Receptor (IGF1R) or Insulin Receptor Inhibitors with Immune Checkpoint Inhibitors in Management of Triple-Negative Breast Cancer (UCLA Case No. 2020-872)

UCLA researchers in the Department Joe C. Wen School of Nursing have developed a novel targeted therapy for triple-negative breast cancer with a potential synergy with immunotherapy. BACKGROUND: Triple-negative breast cancer (TNBC) accounts for about 10-15% of women with breast cancer (BC), but its mortality rate is disproportionally high, causing...

Published: 10/6/2025 | Inventor(s): Nalo Hamilton

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Metabolism And Endocrinology, Diagnostic Markers > Cancer

1 2 3 4 5 6 7 8 9 10 ...